<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820608</url>
  </required_header>
  <id_info>
    <org_study_id>OphthalmicaEI</org_study_id>
    <nct_id>NCT04820608</nct_id>
  </id_info>
  <brief_title>Transepithelial Customized Cross-linking</brief_title>
  <official_title>Epithelium-on Customized Cross-linking for Keratoconus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthalmica Eye Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ophthalmica Eye Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Customized remodeled vision (CuRV) is a new corneal cross-linking protocol for keratoconus,&#xD;
      combining a transepithelial approach with customized energy application. Our aim is to&#xD;
      follow-up our patients and establish the short-and long-term results of CuRV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Customized remodeled vision is a protocol for oxygen-boosted, tranespithelial cross-linking,&#xD;
      customized to apply higher energy at the apex of the cone, relatively lower to the cone area&#xD;
      and none to healthy cornea. Thus CuRV promises to halt keratoconus progression,&#xD;
      simultaneously offering potential for relatively good visual rehabilitation.Our primary&#xD;
      outcomes involve spectacle-corrected distance visual acuity and changes in corneal&#xD;
      topography/tomography and OCT parameters. These parameters include Kmax, thinnest corneal&#xD;
      pachymetry, maximal anterior and posterior elevation, the Fourier analysis-derived&#xD;
      irregularity index, and demarcation line depth.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spectacle-corrected distance visual acuity</measure>
    <time_frame>1-3-6 months, 1 year, 2 years</time_frame>
    <description>Measurements will be performed on Early Treatment of Diabetic Retinopathy Study charts in logMAR units</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kmax</measure>
    <time_frame>1-3-6 months, 1 year, 2 years</time_frame>
    <description>Maximal corneal keratometric value measured on Scheimpflung corneal tomography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demarcation line depth</measure>
    <time_frame>1 month</time_frame>
    <description>Measurements will be performed at 1st postoperative month, when the demarcation line is most visible, on anterior segment optical coherence tomography. The measurement will be performed manually on the scan approximating the thinnest corneal location with the device-native caliper set at 1:1μm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thinnest corneal pachymetry</measure>
    <time_frame>1-3-6 months, 1 year, 2 years</time_frame>
    <description>Values as indicated on Scheimpflung corneal tomography device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal anterior &amp; posterior elevation</measure>
    <time_frame>1-3-6 months, 1 year, 2 years</time_frame>
    <description>Values as indicated on the Belin Ambrosio Enhanced Ectasia module of the Scheimpflung tomography device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fourier analysis-calculated maximum decentration</measure>
    <time_frame>1-3-6 months, 1 year, 2 years</time_frame>
    <description>Values as indicated on the Fourier analysis module of the Scheimpflung tomography device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regularization index</measure>
    <time_frame>1-3-6 months, 1 year, 2 years</time_frame>
    <description>Regularization index was proposed by Seiler et al. The measurement will be performed using the maximum flattening and steepening on the Comparison display of the Scheimpflung tomography device.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Customized, transepithelial cross-linking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study patients will be treated according to the customized remodeled vision protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cross-linking</intervention_name>
    <description>Oxygen-boosted, epithelium-on, customized cross-linking. Highest UV-A application is focused on the apex of the cone. The cone area receives a moderate amount of UV-A, while healthy cornea is spared.</description>
    <arm_group_label>Customized, transepithelial cross-linking</arm_group_label>
    <other_name>Customized remodeled vision</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Topographic evidence of keratoconus:&#xD;
&#xD;
          -  maximum corneal curvature (Kmax) ≥47.00 D,&#xD;
&#xD;
          -  localized steepening on topographic maps,&#xD;
&#xD;
          -  localized elevation in the anterior and posterior corneal surfaces.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to riboflavin&#xD;
&#xD;
          -  Thinnest corneal pachymetry &lt; 380 μm&#xD;
&#xD;
          -  History of corneal surgery, including previous cross-linking&#xD;
&#xD;
          -  Corneal scarring&#xD;
&#xD;
          -  Aphakia&#xD;
&#xD;
          -  Pseudophakia&#xD;
&#xD;
          -  Any visually significant ocular condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miltos Balidis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmica Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmica Eye Institute</name>
      <address>
        <city>Thessaloníki</city>
        <state>Kalamaria</state>
        <zip>54655</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Seiler TG, Fischinger I, Koller T, Zapp D, Frueh BE, Seiler T. Customized Corneal Cross-linking: One-Year Results. Am J Ophthalmol. 2016 Jun;166:14-21. doi: 10.1016/j.ajo.2016.02.029. Epub 2016 Mar 2.</citation>
    <PMID>26944278</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>keratoconus</keyword>
  <keyword>cross-linking</keyword>
  <keyword>transepithelial</keyword>
  <keyword>oxygen-boosted</keyword>
  <keyword>customized</keyword>
  <keyword>CXL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

